Furthermore, there is anecdotal evidence that biologics licensed for use in adults with RA, such as other anti-TNF therapies (infliximab), the IL-1 receptor antagonist anakinra and the B-inhibitor rituximab, are also being prescribed in CYP with JIA [6–8]. The gene discussed is TNF; the disease is juvenile idiopathic arthritis.